Funding for this research was provided by:
National Cancer Institute (1R21CA205430)
Received: 20 December 2017
Accepted: 16 February 2018
First Online: 6 March 2018
Ethics approval and consent to participate
: All samples were collected in accordance with the Dana-Farber Harvard Cancer Center Institutional Review Board (IRB)-approved protocol. All patients provided written consent prior to blood collection.
: Not applicable.
: F.S. Hodi is a consultant of Merck. Bristol-Myers Squibb provided research funding to the CIO/Dana-Farber. No other authors declare competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.